[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Laskar S, Bahl G, Muckaden MA, Nair R, Gupta S, Bakshi A, Gujral S, Shet T, Shrivastava SK, Dinshaw KA: Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer; 2007 Aug 15;110(4):816-23
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
  • BACKGROUND: The purpose was to evaluate the prognostic factors and treatment outcome of Indian patients with primary diffuse large B-cell lymphoma (DLBCL) of the tonsil treated at a single institution.
  • METHODS: In all, 121 patients with DLBCL of the tonsil, treated at the Tata Memorial Hospital, Mumbai, India, from January 1990 to December 2002, were included.
  • Treatment consisted of a combination of chemotherapy (CTh) and radiotherapy (RT) for the majority of patients (69.4%).
  • Among those receiving RT, 64% received an RT dose of > or =45 Gy.
  • The complete response (P = .053), DFS (P = .039), and OS (P = .014) rates were significantly better for patients receiving an RT dose > or =45 Gy.
  • A combined modality treatment, consisting of CTh and RT (with an RT dose of > or =45 Gy), results in a satisfactory outcome in patients with this uncommon neoplasm.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. India. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582622.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Mohammadianpanah M, Gramizadeh B, Omidvari Sh, Mosalaei A: Radiation-induced chondrosarcoma of the maxilla 7-year after combined chemoradiation for tonsillar lymphoma. J Postgrad Med; 2004 Jul-Sep;50(3):200-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced chondrosarcoma of the maxilla 7-year after combined chemoradiation for tonsillar lymphoma.
  • Radiation-induced sarcoma is a rare complication of radiation therapy.
  • An 80-year-old Persian woman developed radiation-induced chondrosarcoma of the left maxilla 7 years after combined chemotherapy and external beam radiation therapy for the Ann Arbor stage IE malignant lymphoma of the right tonsil.
  • [MeSH-major] Chondrosarcoma / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / radiotherapy. Maxillary Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Time Factors

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15377806.001).
  • [ISSN] 0022-3859
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. Mele L, Pagano L, Equitani F, Chiusolo P, Rossi E, Zini G, Teofili L, Leone G: Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature. Haematologica; 2000 May;85(5):544-8
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature.
  • In this paper we describe a case of a 65-year old man with a lymphoid blastic crisis of a chronic granulocytic leukemia occurring seven years after a palatine tonsillar non-Hodgkin's lymphoma treated with chemotherapy and radiation therapy.
  • The patient died within a few months, unresponsive to any treatment.
  • [MeSH-minor] Aged. Bone Marrow Cells / pathology. Cytogenetics. Fatal Outcome. Fusion Proteins, bcr-abl / genetics. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Neoplasms, Second Primary. Palatine Tonsil / pathology. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800174.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] ITALY
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 40
  •  go-up   go-down


Advertisement
4. Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N: Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol; 2005 Apr;84(4):223-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of tonsillar lymphoma: a 10-year experience.
  • Primary extranodal non-Hodgkin's lymphomas of the head and neck account for 10-20% of all non-Hodgkin's lymphomas.
  • Primary tonsillar lymphoma accounts for less than 1% of head and neck malignancies, although the tonsil is the most common primary extranodal site of head and neck non-Hodgkin's lymphomas.
  • In this study we analyzed our cases of tonsillar lymphoma treated in our institution during the last 10 years to compare the finding of this study with those of previous studies.
  • We reviewed the cases of tonsillar lymphoma treated in the Radiation Oncology Department of Shiraz University from 1992 to 2002.
  • The patients were treated by combined chemotherapy [a median of six cycles of a CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisolone)] and radiation therapy (40-50 Gy to the primary site and neck).
  • Chemotherapy mainly preceded radiotherapy, although the sequence of radiotherapy and chemotherapy was determined by individual physicians and patients' choice.
  • Median and mean age was 48 and 44 years (range: 22-76 years), respectively, at the time of diagnosis, with a male to female ratio of 1.2:1.
  • The patients were treated by combined chemotherapy and radiation therapy.
  • All patients developed some degree of oropharyngeal mucositis.
  • A late fatal side effect was observed in one patient who developed radiation-induced sarcoma 7 years after initial diagnosis and died 8 months later without evidence of recurrent lymphoma.
  • At the time of last follow-up, all patients but one were alive.
  • Age, sex, stage, bulk of disease, performance status, number of chemotherapy cycles, number of involved sites, histologic subtypes, and radiation dose were analyzed as prognostically significant for disease-specific survival in our cases.
  • Combined chemotherapy and radiation therapy is safe, highly effective, and probably curative for most patients with primary tonsillar lymphoma.
  • [MeSH-major] Combined Modality Therapy / methods. Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant / adverse effects. Remission Induction / methods. Retrospective Studies. Risk Factors. Survival Rate. Tonsillectomy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15042316.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • METHODS: Clinical data of 89 naive patients with NHL of the tonsil, treated from May 1990 to Jan.
  • Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • Of the 89 patients, 58 (72%) received radiochemotherapy, 19 (21%) received radiotherapy alone, 3 received chemotherapy alone, and 1 received radiochemotherapy combined with rituximab.
  • Cox regression multivariate analysis showed that the survival rate was correlated to the value of international prognostic index (IPI), and whether the patient had primary refractory or relapsed disease, but was not correlated to sex, age, pathologic subtype, B symptoms, and bulky disease.
  • CONCLUSIONS: Most patients with NHL of the tonsil are at early stages, with good prognosis.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • Primary refractory, relapse, and IPI>1 are independent prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Souabni L, Elleuch M, Amira C, Sellami S: Malignant lymphoma of the tonsil in a patient with Behçet's disease. Joint Bone Spine; 2008 Oct;75(5):616-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the tonsil in a patient with Behçet's disease.
  • Several connective tissue diseases such as rheumatoid arthritis and polymyositis are associated with cancer.
  • We report a case of lymphoma during the course of Behçet disease.
  • A 46-year-old man with a 14-year history of Behçet disease was diagnosed with non-Hodgkin malignant lymphoma of the right tonsil.
  • He met international criteria for Behçet disease, which manifested as refractory oral ulcers requiring dapsone treatment.
  • He achieved a complete remission of the lymphoma after three chemotherapy courses and local radiation therapy (45 Gy).
  • [MeSH-major] Behcet Syndrome / pathology. Lymphoma, Non-Hodgkin / pathology. Tonsillar Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Remission Induction

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804394.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Ree HJ, Kikuchi M, Lee SS, Ohshima K, Yang WI, Ko YH, Cho EY, Rhee JC: Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization. Hum Pathol; 2002 Jul;33(7):732-40
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization.
  • Focal follicular features in diffuse large B-cell lymphomas (DLBCLs) are bound to raise the question of follicular lymphoma (FL) with diffuse areas, because the diagnosis of FL is based on the presence of follicular areas, even though focal.
  • We report 7 cases of primary tonsillar DLBCLs with focal follicular features that presented with morphologic, immunohistochemical, and biological features distinct from those of FL.
  • Five of 7 patients were younger than 60, the median age of other patients with primary tonsillar DLBCL.
  • After chemotherapy or radiotherapy, complete remission was achieved with ease in all patients, but 2 patients who were treated with chemotherapy alone relapsed at 24 and 30 months.
  • In conclusion, tonsillar DLBCL includes a small (10%) but distinct subgroup that warrants distinction from FL with predominant diffuse areas or de novo DLBCL.
  • It appears that the focal follicular features in tonsillar DLBCL likely represent follicular colonization of marginal zone B-cell lymphoma, probably high-grade, if the possibility of FL is excluded.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Palatine Tonsil / pathology. Tonsillar Neoplasms / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12196925.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


8. Tsujioka T, Wada H, Suemori S, Sadahira Y, Sugihara T: [CD56-positive peripheral T-cell lymphoma primarily presenting with tonsillar swelling]. Rinsho Ketsueki; 2004 Oct;45(10):1119-23
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD56-positive peripheral T-cell lymphoma primarily presenting with tonsillar swelling].
  • A 51-year-old woman was admitted to our hospital with tonsillar swelling.
  • After tonsillectomy was performed, she was diagnosed as having CD56-positive T-cell lymphoma, mainly composed of small and medium-sized atypical cells.
  • We provided MCEC therapy followed by autologous peripheral blood stem cell transplantation, and complete remission (CR) was achieved.
  • It is rare for CD56-positive T-cell lymphoma to occur primarily in the tonsils.
  • Because small bowel ulcers were revealed during the course of induction chemotherapy, we report a valuable case in which suspected CD56-positive enteropathy-type T-cell lymphoma (ETL) occurred primarily in the tonsils.
  • [MeSH-major] Ileal Neoplasms. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / therapy. Neoplasms, Second Primary. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Antigens, CD56 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Middle Aged. Neoplasm Staging. Nitrosourea Compounds / administration & dosage. Peripheral Blood Stem Cell Transplantation. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553048.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Nitrosourea Compounds; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


9. Ueda T, Tsutani H: [Primary extranodal malignant lymphoma]. Nihon Rinsho; 2000 Mar;58(3):673-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary extranodal malignant lymphoma].
  • Primary extranodal lymphoma with high frequency and/or unique feature in Japan is discussed.
  • Waldeyer ring lymphoma is most frequent(30%).
  • Most tumors consist of diffuse, large cell type of B cell.
  • Gastrointestinal lymphoma is another frequent lymphoma.
  • Surgical rejection followed by chemotherapy and radiation therapy achieved high response.
  • Pyothorax-associated lymphoma is a unique entity reported in Japan.
  • In intravascular lymphomas, lymphoma cells regionally exist in small vessel and are diffuse, large cell type of B cells.
  • Bone lymphoma is found in 4-8%.
  • [MeSH-major] Gastrointestinal Neoplasms. Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Tonsillar Neoplasms
  • [MeSH-minor] Bone Neoplasms / therapy. Combined Modality Therapy. Empyema, Pleural / complications. Humans. Prognosis. Survival Rate. Vascular Neoplasms / therapy

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741145.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 12
  •  go-up   go-down


10. Wang CP, Hsieh CY, Chang YL, Lou PJ, Yang TL, Ting LL, Ko JY: Postirradiated neuroendocrine carcinoma of the sinonasal tract. Laryngoscope; 2008 May;118(5):804-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this present study, we report our treatment experience with sinonasal NEC.
  • RESULTS: Ten tumors were primary NEC without previous radiation, and eight tumors were postirradiated NEC occurring within the radiation field for previous nasopharyngeal carcinoma in six patients and tonsillar lymphoma in one and neck metastasis of unknown primary origin in one, with an interval between previous radiotherapy and diagnosis of NEC from 82 to 385 months, with a mean of 197 months.
  • Three patients received induction chemotherapy or primary radiotherapy with further definitive treatment.
  • In comparing primary NEC with postirradiated NEC, they were similar in age, sex distribution, stage, pathology, and treatment, and the 5-year overall survival rates were 70% and 62.5%, respectively.
  • The prognoses of postirradiated NEC and primary NEC appear to be similar despite the relatively short follow-up period in the postirradiated NEC group.
  • [MeSH-minor] Adult. Aged. Carcinoma, Small Cell / radiotherapy. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Combined Modality Therapy. Female. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Humans. Lymphoma / pathology. Lymphoma / radiotherapy. Male. Maxillary Neoplasms / secondary. Maxillary Neoplasms / surgery. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Radiotherapy Dosage. Retrospective Studies. Tonsillar Neoplasms / pathology. Tonsillar Neoplasms / radiotherapy. Tonsillar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520182.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Chang DT, Mendenhall NP, Lynch JW, Morris CG, Olivier KR: Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring. Am J Clin Oncol; 2009 Jun;32(3):233-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring.
  • PURPOSE: To determine the long-term outcome of patients treated at the University of Florida for aggressive non-Hodgkin lymphoma (NHL) of Waldeyer's ring.
  • Of this group, 20 patients were treated with RT alone and 26 with combined-modality therapy (CMT) with the addition of chemotherapy: 24 patients with induction and 2 with concurrent or adjuvant chemotherapy.
  • CONCLUSIONS: Similar to other sites, out-of-field recurrences are the primary pattern of failure for NHL of Waldeyer's ring.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Tonsillar Neoplasms / drug therapy. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433961.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Gao Y, Li Y, Yuan Z, Zhao L, Liu X, Gu D, Qian T, Yu Z: [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):483-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil].
  • OBJECTIVE: To investigate the prognostic value of the size of primary tumor (T staging) and international prognostic index (IPI) for patients with non-Hodgkin's lymphoma (NHL) of the tonsil, and to recommend the treatment strategy for early stage patients.
  • METHODS: 306 patients with untreated NHL of the tonsil were reviewed.
  • Twelve stage I patients were given radiotherapy alone and 23 stage II patients were given combined modality therapy (CMT).
  • For patients with stage II lesion, 57 were given radiotherapy alone, 2 chemotherapy alone and 119 CMT.
  • Chemotherapy was the main treatment in patients with stage III or IV lesions.
  • RESULTS: The 5-year cancer specific survival (CSS) was 74% for patients with T(1), 59% for T(2), 56% for T(3) and 26% for T(4), respectively (P = 0.000).
  • CONCLUSION: The T staging of the primary tumor and IPI are the important prognostic factors of patients with NHL of the tonsil.
  • Combined modality therapy significantly improves the disease free survival of stage II patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Tonsillar Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485504.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Gao YH, Li YX, Zhao LJ, Yuan ZY, Liu XF, Yu ZH: [Treatment of early stage primary tonsil non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2003 Apr;24(4):190-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of early stage primary tonsil non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the treatment for patients with early stage primary tonsil non-Hodgkin's lymphoma (NHL).
  • METHODS: Two hundred and thirteen patients with previously untreated early stage primary tonsil NHL were reviewed.
  • The primary treatment for stage I was radiotherapy alone in 12 and combined modality therapy (CMT) in 23 patients.
  • The primary treatment for stage II was radiotherapy alone in 57,chemotherapy alone in 2, and CMT in 119 patients.
  • RESULTS: The 5-year overall survival, cancer specific survival (CSS) AND disease-free survival (DFS) for the early stage primary tonsil non-Hodgkin's lymphoma were 65%, 70% and 61%, respectively.
  • There was no significant difference of efficacy between the two treatment s for the patients with stage I disease.
  • CONCLUSION: Patients with stage I tonsil non-Hodgkin's lymphoma treated with radiotherapy alone or CMT can achieve an excellent outcome.
  • It was suggested that CMT should be used for the patients with early stage primary tonsil non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12864949.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Zeglaoui I, Belcadhi M, Sriha B, Bouzouita K: Nasal NK/T-cell lymphoma in the paediatric population. Two case reports. B-ENT; 2009;5(2):119-23
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal NK/T-cell lymphoma in the paediatric population. Two case reports.
  • Nasal natural killer (NK)/T-cell lymphoma is an uncommon disease, and only a few paediatric cases are found in the literature.
  • We report 2 cases of NK/T-cell lymphoma occurring in children.
  • The primary site was the the nasal cavity in the first case (5-year-old girl) and the tonsil in the second case (4-year-old boy).
  • Both underwent an aggressive chemotherapy regimen.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy. Tonsillar Neoplasms / diagnosis. Tonsillar Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670600.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


15. Ezzat AA, Ibrahim EM, El Weshi AN, Khafaga YM, AlJurf M, Martin JM, Ajarim DS, Bazarbashi SN, Stuart RK, Zucca E: Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck; 2001 Jul;23(7):547-58
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients.
  • BACKGROUND: Waldeyer's ring (WR) is the primary site of non-Hodgkin's lymphoma (NHL) involvement in approximately 5% to 10% of all lymphoma patients, and it accounts for more than half of all primary extranodal lymphomas of the head and neck.
  • Seventy five (58%), 46 (35%), and 9 (7%) patients had primary tonsillar, nasopharyngeal, and base of the tongue lymphoma, respectively.
  • Chemotherapy (CT) was given to 58 (45%) patients, whereas 26 (20%) received radiation therapy (RTX), and 46 (35%) were managed with a combination of chemotherapy and radiotherapy (CMT).
  • One hundred nine (84%), 16 (12%), and 5 (4%) patients attained complete remission (CR), partial remission (PR), and treatment failure, respectively, with no difference in CR rates between the three therapeutic modalities.
  • Of those patients with DLC, 90 (83%), 15 (14%), and 4 (3%) demonstrated CR, PR, and treatment failure, respectively.
  • Cox proportional hazards model identified primary tonsillar site and a low-risk group as defined by the modified IPI were associated with favorable OS.
  • The median event-free survival was 82.3 months, with the primary tonsillar site, and low-risk modified IPI group were associated with favorable EFS in a multivariate analysis.
  • The CMT was not associated with a superior OS compared with either of the single modality treatments; however, it was associated with more favorable EFS.
  • Primary tonsillar site and the low-risk group of the modified IPI predicted favorable OS and EFS.
  • CMT is probably superior to single modality treatment; however, prospective studies are warranted.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 John Wiley & Sons, Inc.
  • (PMID = 11400243.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Singh SK, Gupta AK, Jha V, Kohli HS, Gupta KL, Minz M, Sakhuja V: Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy. Transplant Proc; 2006 Sep;38(7):2088-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of oropharyngeal cancer in renal transplant recipients without cessation of immunosuppressive therapy.
  • Reduction or cessation of immunosuppressive therapy has been advocated in these cases to prevent tumor progression and recurrence.
  • We evaluated the outcome of treatment of oropharyngeal cancer (OC) after renal transplantation without cessation of immunosuppressive therapy.
  • METHODS: The database of patients with OC after renal transplantation was analyzed with respect to age, sex, type of immunosuppression, interval between transplantation and diagnosis of cancer, as well as method of treatment and survival.
  • RESULTS: Thirty one (2.06%) renal transplant recipients developed malignancy including 6 (20%) with OC.
  • Lingual cancer was seen in three, and one each showed an isolated tonsillar lymphoma, a parotid carcinoma, or a carcinoma of the larynx with only the last having had two other malignancies in the past.
  • Average time from transplantation to diagnosis of OC was 106 months.
  • The interval was the shortest (2 years) for tonsillar lymphoma in an 18-year-old patient who received cyclosporine and showed features of left follicular tonsillitis.
  • The patient with advanced carcinoma of the larynx did not receive any treatment and succumbed within 3 months.
  • The dose of cyclosporine was reduced in the lymphoma case but immunosuppression was not altered in the other patients.
  • CONCLUSION: Comprehensive treatment of OC after renal transplantation without withdrawing the immunosuppression prolonged the life of these patients with functioning grafts.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Kidney Transplantation / immunology. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980008.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


17. Qi J, Fan X, Wang C, Ma J, Tang H: [Unilateral tonsillar enlargement and malignant tonsillar lymphoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Sep;16(9):469-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unilateral tonsillar enlargement and malignant tonsillar lymphoma].
  • OBJECTIVE: To study clinic characters of malignant lymphoma in patients with unilateral tonsillar enlargement for early discover and synthetic therapy clinic characters of malignant lymphoma patients with unilateral tonsillar enlargement for early discover and synthetic therapy.
  • METHOD: 10 cases of non-Hodgkin's lymphoma (NHL) out of 100 unilateral tonsillar enlargement patients given tonsillectomy were treated with combined chemotherapy.
  • CONCLUSION: Progressing unilateral swollen tonsil found in a short time with suspicious appearance should be given tonsillectomy for histopathology; upper airway and systematic symptoms such as fever and rigors, night sweats; lymphatic enlargement in cervical, axillary, inguinal region; hepatosplenomegaly should be thought of main traits of malignant lymphoma, and hyposensitivity to medicine should be taken malignant lymphoma into account.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Tonsillar Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Tonsillectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15515534.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Gurkaynak M, Cengiz M, Akyurek S, Ozyar E, Atahan IL, Tekuzman G: Waldeyer's ring lymphomas: treatment results and prognostic factors. Am J Clin Oncol; 2003 Oct;26(5):437-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Waldeyer's ring lymphomas: treatment results and prognostic factors.
  • Optimal management of patients with localized Waldeyer's ring (WR) lymphoma remains controversial due to the lack of randomized studies and heterogenous grouping of most reported series.
  • In this retrospective study, we have evaluated the possible prognostic factors and treatment outcome of WR non-Hodgkin's lymphoma.
  • Between December 1993 and February 2000, 32 patients with WR lymphoma, stage I (11 patients) and stage II (21 patients) were treated.
  • Combined chemotherapy and radiotherapy was the primary modality of therapy for intermediate or high-grade lymphoma.
  • Chemotherapy was median 6 courses of CHOP (cyclophosphamide, doxorubicin (Adriamycin), vincristine, and prednisolone) in 26 patients and CEOP (cyclophosphamide, doxorubicin, etoposide, and prednisone).
  • Radiotherapy volume was involved field and the median dose was 40 Gy.
  • Two patients developed recurrence, both salvaged with further chemotherapy.
  • Our results suggest that combined chemotherapy and involved field radiotherapy is appropriate treatment for stage I-II WR lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Nasopharyngeal Neoplasms / mortality. Tongue Neoplasms / mortality. Tonsillar Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14528067.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yamazaki R, Takayama N, Hamano Y, Mori T, Okamoto S, Ikeda Y: [Localized recurrence of acute lymphoblastic leukemia-L3 in the tonsil after 3-years' remission]. Rinsho Ketsueki; 2002 Nov;43(11):1004-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localized recurrence of acute lymphoblastic leukemia-L3 in the tonsil after 3-years' remission].
  • Recurrence of Burkitt's lymphoma (BL)/acute lymphoblastic leukemia (ALL)-L3 after a long-term remission is very rare.
  • We herein report on a case of BL/ALL-L3 indicating solitary recurrence in the tonsil after a 3-year remission.
  • A 50-year-old man was diagnosed as having Burkitt's type ALL-L3 with involvement of the stomach and abdominal lymph nodes.
  • He was treated with intensive chemotherapy consisting of methotrexate and cyclophosphamide (ALL-BFM86 protocol), and a complete remission was achieved.
  • After sustaining the remission for three years, a swelling of the right tonsil was observed, which was histologically diagnosed as Burkitt's lymphoma.
  • The pattern of c-myc rearrangement of the tonsil demonstrated by southern blotting was identical to that of the bone marrow at initial presentation and the recurrence of primary ALL-L3/BL was thus confirmed.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Tonsillar Neoplasms / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Recurrence. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12508487.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Manganini M, Serafini M, Bambacioni F, Casati C, Erba E, Follenzi A, Naldini L, Bernasconi S, Gaipa G, Rambaldi A, Biondi A, Golay J, Introna M: A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. Hum Gene Ther; 2002 Oct 10;13(15):1793-807
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors.
  • We have investigated the capacity of two human immunodeficiency virus type 1-derived lentivectors, differing in the presence of a 118-bp pol fragment containing the cPPT/CTS element, to transduce human normal primary cells of different hematopoietic lineages.
  • Still higher transduction of T lymphocytes can be achieved after stimulation with phytohemagglutinin and interleukin 2 (up to 78% with the cPPT vector vs. 42% with the no-cPPT vector).
  • Finally, both viruses do not transduce either resting or proliferating tonsillar B lymphocytes.
  • [MeSH-minor] B-Lymphocytes / drug effects. B-Lymphocytes / virology. Cell Division / drug effects. Fibroblasts. Genes, Reporter. Green Fluorescent Proteins. Humans. Interleukin-15 / pharmacology. Interleukin-2 / pharmacology. Kidney. Luminescent Proteins / analysis. Luminescent Proteins / genetics. Lymphoma, Follicular / pathology. Moloney murine leukemia virus / genetics. Phytohemagglutinins / pharmacology. Terminal Repeat Sequences. Tumor Cells, Cultured

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12396613.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-15; 0 / Interleukin-2; 0 / Luminescent Proteins; 0 / Phytohemagglutinins; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down






Advertisement